… patients treated with dapagliflozin experienced clinically meaningful improvements in heart
failure–related symptoms, functional status … patients with and without type 2 diabetes mellitus. …

… : In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12
weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing …

… , and improved symptoms in patients with heart failure and … the effects of dapagliflozin on a
broad range of health status outcomes… symptom burden, functional status, and quality of life in …

… -2i in patients with established HFrEF with and without T2D. It will assess whether the …
dapagliflozin improves HF biomarkers, symptoms and functional status in this high-risk patient …

… and Functional Status in Patients With … effect of dapagliflozin on biomarkers of fatty acid
metabolism was consistent across left ventricular ejection fraction (LVEF), but the ketogenic effect …

… and Functional Status in Patients With HF With Reduced Ejection Fraction)… effects of
dapagliflozin on HF disease-specific biomarkers (NT-proBNP) and health status (symptoms, function…

… and structure; however, less is known about dapagliflozin. The purpose of the current work …
of dapagliflozin and cardiac biomarkers as well as the cardiac structure in a cohort of patients …

… -HF (Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients
With Preserved Ejection Fraction Heart Failure) trials, dapagliflozin has been previously …

… with heart failure and reduced ejection fraction (HFrEF). … of dapagliflozin in a real-world
population of HFrEF patients … included HFrEF patients who were initiated on dapagliflozin therapy …

… In another small study of 75 patients with T2DM randomized to dapagliflozin, … for T2DM
may exert favorable cardiovascular effects. Concentrations of each biomarker measured in this …